HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease. Sean Korbitz had his first bout with cancer — a brain tumor discovered after six ... Cure Today: Welireg Made a von Hippel-Lindau Survivor Feel Like a 'Medical Miracle' Nasdaq: Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors ascopubs.org: Fatal Intracranial Hemorrhage With Belzutifan in von Hippel-Lindau Disease–Associated Hemangioblastoma: A Case Report Fatal Intracranial Hemorrhage With Belzutifan in von Hippel-Lindau Disease–Associated Hemangioblastoma: A Case Report Nature: Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study Moderate to advanced chronic kidney disease is an underappreciated burden of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC) treated with surgery, which also includes frequent disease ...
The New England Journal of Medicine: Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease The cause of von Hippel–Lindau disease is excess activity of the HIF-2α pathway. A total of 61 patients with renal cell carcinoma and other proliferative manifestations of the hypoxia-induced ...
